Clinical Trial Update: Ravulizumab and COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for ravulizumab in COVID-19 and related thrombotic microangiopathy conditions; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Thrombotic Microangiopathy

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Covid19, Thrombotic Microangiopathies | Phase 3 | Status: UNKNOWN